Unlock Editor Digest for FREE
Roela Khalaf, Ft Editor, selects his favorite stories in this weekly newsletter.
Drug hikma is speeches to colleagues around the world to prepare to sell a generic version of Ozemple, as Novo Nordisk’s blockbuster patents start next year.
FTSE 100 Group is running to create a generic form of semaglutide, the active ingredient of medicines. The patents of the branded versions due to canada expiry, China, India and Brazil in 2026, and other markets between 2028 and 2032.
Riad Mishlawi, Hikma’s chief executive, said the effect of new drug class has a similar effect on the first antibiotic penicillin.
“It’s not just because of weight loss… Because the weight causes many other diseases,” he said. “So if you treat it, indirectly, you treat a lot of diseases. So cause it’s a big craze and many people jump it.”
The analysts estimate the size of the weight loss of battle to weigh like anywhere between $ 80bn and $ 140bn. Mishlawi says current medicines “is just the beginning” because there are many new medicine drugs developed.
Some US Health Insurers and several European Health Systems have prevented access to drugs due to cost implications provided the number of patients overweight. In the US, the price of the list for a month of Wegegy supply more than $ 1,300.
Generic drugs are likely to be 80 to 85 percent more cheaper than branded drugs, according to US food and US administration.
If patents of weight loss of medications expire, generic versions are likely to be in high demand.
Novo Nordisk says patent expiry is a “natural part of the pharmaceutical product” and the company “explores new molecules, combinations of treatments, similar to organizational opportunities”.
“The market potential and the opportunity to treat many patients continues to remain strong,” as it.
Hikma was founded in Jordan and was the second largest drug in the Middle East and North Africa by selling, after the French pharmaceutisical company Sanafi.
Mishlawi says the weight of weight loss is very popular in the region. He added that the company “often leads to be the first” Maker of Generic Products in the Middle East. Company shares have risen 17 percent last year.
Hikuma launches Liraglutide, a generic version of an early Novo Nordisk Resper Drop, in the US in December. Liraglutide, Novo sold Victoza for Diabenetes and Saxenda for weight loss, helped by 15 percent of Ozemptic or Wegovy.
Mishlawi said the price of Generic Liraglutide Prompts even if only two drugmakers sell it – Hikma and Teva – in the US.
“I don’t think it’s stone on rock, but I think one or two players, it’s easy to get to that level,” he said.